天麻钩藤饮对肝阳上亢型高血压病患者血浆SOD、MDA的影响

目的：探讨天麻钩藤饮对高血压病(肝阳上亢型)患者疗效和血清超氧化物岐化酶(SOD)活性和丙二醛(MDA)的影响，为临床高血压病患者的治疗提供理论依据。方法：在门诊或住院病例中选择符合诊断条件的112例患者，随机分为天麻钩藤饮组(60例)和对照组(52例)，两组治疗4周后，观察治疗前后血压的改变及血清SOD、MDA的变化。结果：两组患者治疗后血压均明显降低，两组比较差异无显著性(P>0．05)。天麻钩藤饮组和对照组的SOD活性在治疗前分别为(85．6±11．2)U／mL和(86．3±12.5)U／mL，在治疗后为(98．1±12．8)U／mL和(95．1±13．2)U／mL，两组治疗后比较差异有显著性(P<0．01)；MDA在治疗前为(6．28±1．65)nmol／L和(6．23±1．58)nmol／L，在治疗后为(4．08±1．30)nmol／L和(5．11±1．39)nmol／L，两组治疗后比较差异有显著性(P<0．01)。结论：天麻钩藤饮能降低高血压患者血压，并能通过提高SOD活性和降低MDA含量而保护机体，提高机体的抗氧化能力。     

天麻钩藤饮对肝阳上亢型原发性高血压患者血浆内皮素的影响

目的 探讨天麻钩藤饮对原发性高血压(肝阳上亢型)患者血压和血浆内皮素的影响,为临床高血压患者的治疗及康复措施介入提供有力的理论依据.方法 所有病例均为中南大学湘雅医院 2001- 09/2002- 09住院或门诊患者,采用随机分组法将患者分为 2组,天麻钩藤饮组( 52例),男 41例,女 11例,平均年龄( 55± 4)岁.对照组( 50例),男 41例,女 9例,平均年龄( 54± 5)岁.纳入标准符合 1999年世界卫生组织修订的高血压诊断分级标准及肝阳上亢症辨证标准.排除标准除外冠心病、脑卒中、肾功能不全、Ⅲ级高血压的患者.天麻钩藤饮组以天麻钩藤饮治疗,对照组以尼群地平片治疗,两组均连续治疗 4周.两组治疗 4周后,观察治疗前后血压的改变及血浆内皮素的变化.结果 天麻钩藤饮组血压明显降低( t=2.400,P《 0.05),对照组血压明显降低( t=2.210,P《 0.05),天麻钩藤饮组治疗前内皮素水平 [(87.96± 13.57) ng/L]明显高于治疗后 [(56.21± 14.00) ng/L]( t=2.651, P《 0.01).结论 天麻钩藤饮能显著降低高血压患者血压,其作用机制可能是通过降低内皮素而发挥作用.     

天麻钩藤饮对肝阳上亢型原发性高血压患者血浆内皮素的影响

目的：探讨天麻钩藤饮对原发性高血压(肝阳上亢型)患者血压和血浆内皮素的影响，为临床高血压患者的治疗及康复措施介入供有力的理论依据。方法：所有病例均为中南大学湘雅医院2001—09／2002—09住院或门诊患者，采用随机分组法将患者分为2组，天麻钩藤饮组(52例)，男41例，女11例，平均年龄(55&;#177;4)岁。对照组(50例)，男41例，女9例，平均年龄(54&;#177;5)岁。纳入标准：符合1999年世界卫生组织修订的高血压诊断分级标准及肝阳上亢症辨证标准。排除标准：除外冠心病、脑卒中、肾功能不全、Ⅲ级高血压的患者。天麻钩藤饮组以天麻钩藤饮治疗，对照组以尼群地平片治疗，两组均连续治疗4周。两组治疗4周后，观察治疗前后血压的改变及血浆内皮素的变化。结果：天麻钩藤饮组血压明显降低(t=2．400，P&;lt;0．05)，对照组血压明显降低(t=2．210，P&;lt;0．05)，天麻钩藤饮组治疗前内皮素水平[(87．96&;#177;13．57)ng／L1明显高于治疗后[(56．21&;#177;14．00)ng／L](t=2．651，P&;lt;0．01)。结论：天麻钩藤饮能显著降低高血压患者血压，其作用机制可能是通过降低内皮素而发挥作用。     

天麻钩藤饮对高血压患者血浆一氧化氮的影响

目的 :观察天麻钩藤饮对高血压 (肝阳上亢型 )患者血浆一氧化氮 (NO)的影响。方法 :10 2例肝阳上亢型高血压患者分为中药组 52例和西药组 50例 ,分别采用中药天麻钩藤饮及西药尼群地平片治疗 ,并于治疗前后检测血压水平及血浆NO的变化。结果 :2组治疗后 ,血压改变差异无显著 (P >0 .0 5) ,而血浆NO的变化 ,中药组明显优于西药组 (P <0 .0 1)。结论 :天麻钩藤饮能显著提高血浆NO水平     

天麻钩藤饮加减联合西药治疗高血压肝阳上亢证42例的疗效

目的 探究天麻钩藤饮加减联合西药在高血压肝阳上亢证治疗中的效果。方法 选择我院2019年10月-2020年11月收治的肝阳上亢证高血压患者84例，按随机数字表法分为两组各42例。对照组口服西药，在上述基础上，研究组联合天麻钩藤饮加减治疗。对比两组治疗总有效率、中医证候积分、血压水平及不良反应。结果 研究组治疗总有效率为95.24%，高于对照组的76.19%，有统计学差异（P＜0.05）；研究组治疗后中医证候积分为（3.06±0.42）分、SBP为（128.54±9.61）mmHg、DBP为（74.10±2.14）mmHg，均低于对照组的（7.84±0.59）分、（138.75±10.39）mmHg、（89.43±2.65）mmHg，有统计学差异（P＜0.05）；两组均未见明显不良反应。结论 高血压肝阳上亢证患者采用天麻钩藤饮加减联合西药治疗能够有效改善临床症状，稳定血压水平，疗效确切，安全可靠，值得推广应用。     

天麻钩藤饮对原发性高血压患者疗效和生活质量的影响

目的:探讨天麻钩藤饮对原发性高血压(肝阳上亢型)的临床疗效,进一步验证天麻钩藤饮的降压作用。方法:观察天麻钩藤饮组(简称天麻组)(60例)和尼群地平组(简称尼群组)(58例)治疗前后的血压水平,临床症状(眩晕、头痛、耳鸣、肢麻、健忘、心悸、面部烘热、烦躁易怒、失眠、口苦)的变化。结果:天麻组与尼群组均有明显的降低血压作用,两组结果比较差异无显著性意义(P>0.05)。在改善临床症状方面天麻组明显优于尼群组(t=2.303,P<0.01)天麻组总有效率91%(55/60),尼群地平组总有效率60%(34/58)。两组治疗后基本日常生活活动能力均明显改善(P<0.05)。天麻组治疗后,健康愉快感、躯体症状、工作表现、情感状态、生活满意度生活质量评分分别为(87.9±8.4),(8.00±3.2),(26.8±4.6),(9.5±7.8),(37.2±4.1)分,均较治疗前犤(72.3±7.8),(11.3±4.5),(19.9±3.9),(11.8±5.1),(33.2±3.2)分犦明显改善(P<0.05)。结论:天麻钩滕饮的降压效果确切,能明显改善原发性高血压患者的临床症状和生活质量。     

天麻钩藤饮及其加减治疗眩晕症的临床研究

【】目的：对比分析天麻钩藤饮及其加减治疗眩晕症的临床效果。方法：随机选取2015年2月-2016年2月经我院诊断并治疗的眩晕症患者120例作为研究对象,分为中医组和西医组,各60例。中医组采用天麻钩藤饮及其加减治疗眩晕症,西医组采用天麻素药物治疗眩晕症;治疗5周后分别记录两组患者的治疗情况,并比较。结果：治疗5周后;中医组临床症状明显比西医组临床症状好; 以及中医组总有效率(95.00%)明显优于西医组(76.67%);p值均<0.05,均具有统计学意义。结论：采用天麻钩藤饮及其加减治疗眩晕症,可以有效的缓解患者出现头昏、眼花等临床症状,治疗效果佳,值得临床应用。     

中药离子导入对颈性眩晕患者血浆降钙素基因相关肽的影响

目的 :观察颈性眩晕患者血浆降钙素基因相关肽 ( CGRP)的水平及单向中频电中药导入治疗后患者血浆 CGRP的改变。方法 :对 34例颈性眩晕患者采用单向中频电中药导入治疗 (导入组 ) ;另 34例口服复方丹参片和眩晕停药物治疗作为对照。治疗前后测定血浆 CGRP。结果 :治疗前 6 8例眩晕患者血浆 CGRP〔导入组( 36 .2 3± 2 2 .78) ng/L,服药组 ( 36 .72± 2 2 .85 ) ng/L〕均低于健康人组〔( 5 2 .2 6± 18.5 3) ng/L,P均 <0 .0 1〕,经单向中频电中药导入治疗后患者血浆 CGRP较治疗前明显升高〔导入组 ( 5 0 .12± 2 0 .6 2 ) ng/L,P<0 .0 5 ;服药组 ( 44 .5 2± 2 3.36 ) ng/L ,P>0 .0 5〕。结论 :CGRP参与了颈性眩晕的病理生理过程。     

天麻钩藤饮治疗肝阳上亢型高血压病40例临床疗效观察

【】目的：观察天麻钩藤饮联合硝苯地平控释片对肝阳上亢型高血压病的临床疗效。方法：将80例肝阳上亢型高血压病患者随机分为治疗组和对照组,各40例。对照组予硝苯地平控释片30mg口服,日一次;治疗组在对照组基础上给予天麻钩藤饮,日一剂,口服。疗程后,记录两组患者的血压及中医症候改善情况。结果：在控制血压方面,治疗组优于对照组(P＜0.05);在改善中医症候方面,治疗组明显优于对照组(P＜0.01)。结论：中药天麻钩藤饮联合西药硝苯地平控释片对肝阳上亢型高血压疗效显著,特别是能明显改善患者的临床症状,值得临床推广。     

卡维地洛对缺血性心肌病患者心功能和N-末端脑利钠肽的影响

【目的】观察卡维地洛对缺血性心肌病 (ICM )患者心功能和N 末端脑利钠肽 (Nt proBNP)的影响。【方法】已接受常规治疗 ,病情稳定的ICM患者 5 6例 ,随机分为两组 :卡维地洛组 (治疗组 ) 30例 ,常规治疗组 (对照组 ) 2 6例。卡维地洛组在常规治疗的基础上加用卡维地洛治疗 ,从小剂量开始 ,逐渐加量至耐受剂量或目标剂量 ,共治疗 4个月。治疗前及治疗后采用超声心动图仪测定左室舒张末期内径 (LVEDD)、左室收缩末期内径 (LVESD)、左室射血分数 (LVEF)、心输出量 (CO) ,并采用ELISA法测定血浆中Nt proBNP的浓度。【结果】治疗 4个月后 ,卡维地洛组较对照组LVEDD(6 0 .2± 8.4vs 6 5 .4± 8.4mm)、LVESD(48.4± 7.4vs5 3.8± 8.6mm)显著下降 (P <0 .0 5 ) ,LVEF(42 .6± 11.3vs 34.5± 12 .4 % )、CO(4.4 2± 1.5 6vs 3.77± 1.6 8L/min)显著升高 (P <0 .0 5 ) ,血浆Nt proBNP浓度 (487± 85vs 5 93± 90pmol/L)显著下降 (P <0 .0 5 )。【结论】卡维地洛能显著改善缺血性心肌病患者的心功能。     

Renin inhibitors

Since the early 1980s, an intensive effort has been focused on the development of orally effective and long-acting inhibitors of renin. During this time, in vitro potency has increased greatly, with several transition-state inhibitor designs yielding inhibitors with subnanomolar IC50 values. In the meantime, both the molecular weight and peptide character of the inhibitors has decreased as important binding elements have been focused into smaller and more stable structures. The resulting inhibitors have shown promising activities in several in vivo models and (in two cases) in man. Nevertheless, renin inhibitors reported to date have limited oral bioavailability and short duration of action, and improvements in both will be necessary for them to compete effectively with ACE inhibitors. Renin inhibitors which have entered clinical studies have at least one naturally occurring amino acid and three or more amide bonds. It is reasonable to expect that continued development will produce wholly nonpeptide inhibitors with still lower MW, and it may be these "second-generation" inhibitors which will succeed as therapeutic agents. Development of orally effective and long-acting inhibitors of renin will enable their long-term antihypertensive efficacy and possible advantages over ACE inhibitor to be investigated.     

Partial Purification of Human Renin Substrate

A two-step purification method is described for the preparation of renin substrate from human plasma. Pooled plasma from women on oral contraceptives is used for the purification. The overall yield of renin substrate is 57%, with a twenty-fold purification. The specific renin substrate content of the preparation, as determined by enzymatic degradation with an excess of human renin, is 2 μg angiotensin I per mg protein. The product has a very low endogenous renin activity and is free from angiotensinase activity. An additional purification step involving affinity chromatography is described. In pilot studies a renin substrate yield of 37% has been achieved, with a hundred-fold purification. The final product has a specific renin substrate content of 10 μg angiotensin I per mg protein. The preparation contains up to 12 different plasma proteins, nine of which have been identified and guantitated.     

Renin substrate in human amniotic fluid

Purified human amniotic fluid renin substrate (RS) was compared to purified plasma RS. RS in plasma and amniotic fluid were similar in molecular weight, isoelectric point and immunological properties.

Immunoreactivity of radio-iodinated amniotic fluid RS was lower than that of plasma RS. Measured by direct radioimmunoassay, RS-levels were only 10–22% of those obtained with indirect assay in 22 amniotic fluid samples. This difference suggests that amniotic fluid RS is less immunoreactive than plasma RS, possibly due to biochemical alteration or complex formation. No such difference in immunoreactivity was noticed in RS of decidual and placental cytosolic fraction.     

Plasma Renin Activity in Diabetic Autonomic Neuropathy

Postural changes in plasma renin activity were studied in three groups of age and duration-matched male diabetics (potent, impotent and with postural hypotension) and in non-diabetic control subjects. Those diabetic subjects with postural hypotension due to automatic neuropathy had no increase in plasma renin activity to the erect posture whereas both the potent and impotent groups had similar plasma renin activity responses to the control subjects. There was a significant inverse correlation between the rise in plasma renin activity on standing and the postural drop in blood pressure (r = 0. 476, P < 0.01) but no correlation with other tests of autonomic reflex function such as the Valsalva manoeuvre and blood pressure response to sustained handgrip. The results suggested that the lesion responsible for the postural hypotension is in the efferent sympathetic pathway. However, neuropathy per se did not wholly explain the decreased postural plasma renin activity response. Diabetic nephropathy, with involvement of cells of juxtaglomerular apparatus, may also be implicated.